Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

Chest

Volumn 124, Issue 1, 2003, Pages 177-185

  Utz, James P ^a   Limper, Andrew H ^a   Kalra, Sanjay ^a   Specks, Ulrich ^a   Scott, John P ^a   Vuk Pavlovic, Zvezdana ^a   Schroeder, Darrell R ^a  

^a MAYO CLINIC   (United States)

Author keywords

BAL; Etanercept; Sarcoidosis; Tumor necrosis factor

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DYSPNEA; FEMALE; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SARCOIDOSIS; THORAX RADIOGRAPHY; TREATMENT FAILURE;

EID: 0038498467     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.1.177     Document Type: Article

References (40)

1. Hillerdal G, Nou E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis. Am Rev Respir Dis 1984; 130:29-32
2. Reich JM, Johnson RE. Course and prognosis of sarcoidosis in nonreferral setting. Am J Med 1985; 78:61-67
3. American Thoracic Society. Statement on sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736-755
4. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52:525-533
5. Siltzbach LE. Sarcoidosis: clinical features and management. Med Clin North Am 1967; 51:483-502
6. Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987; 135: 747-760
7. Sheffield EA. Pathology of sarcoidosis. Clin Chest Med 1997; 18:741-754
8. Kunkel SL, Chensue SW, Strieter RM, et al. Cellular and molecular aspects of granulomatous inflammation. Am J Respir Cell Mol Biol 1989; 1:439-447
9. Kataria YP, Holter JF. Immunology of sarcoidosis. Clin Chest Med 1997; 18:719-739
10. Semenzato G, Agostini C. Immunologic events in the development of interstitial lung disease: the paradigm of sarcoidosis. In: Schwarz M, King T, eds. Interstitial lung disease. 3rd ed. Hamilton, ON, Canada: BC Decker, 1998; 229-250
11. Tracey KJ. Tumour necrosis factor-alpha. The cytokine handbook. 2nd ed. New York, NY: Academic Press, 1994; 289-304
12. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666-3670
13. Chensue SW, Warmington KS, Ruth JH, et al. Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation: local and regional participation of IFN-alpha, IL-10, and TNF. J Immunol 1995; 154:5969-5976
14. Thanhäuser A, Reiling N, Böhle A, et al. Pentoxifylline: a potent inhibitor of IL-2 and IFN-y biosynthesis and BCG-induced cytotoxicity. Immunology 1993; 80:151-156
15. Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31:171-181
16. Kindler V, Sappino A, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731-740
17. Bost TW, Riches DW, Schumacher B, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-α and interleukin-6 but not interleukin-1β. Am J Respir Cell Mol Biol 1994l; 10:506-513
18. Ziegenhagen MW, Benner G, Zissel P, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156:1586-1592
19. Marques LJ, Zheng L, Poulakis J, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999; 159:508-511
20. Zabel P, Schönharting MM, Wolter DT, et al. Oxpentifylline in endotoxaemia. Lancet 1989; 334:1474-1477
21. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155:1665-1669
22. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136
23. American Thoracic Society. Single breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique; statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136:1299-1307
24. American Thoracic Society. Modified Medical Research Council dyspnea scale. ATS News 1982; 8:12-16
25. Ware JE. SF-36 physical and mental health summary scales: a user's manual. Boston, MA: The Health Institute, New England Medical Center, 1994
26. Limper AH, Specks U, Brutinel WM, et al. Interlobar variation in the recovery of bronchoalveolar lavage fluid, cell populations, and angiotensin-converting enzyme in normal volunteers. J Lab Clin Med 1993; 121:785-791
27. Castro M, Morgenthaler TI, Hoffman OA, et al. Pneumocystis carinii induces the release of arachidonic acid and its metabolites from alveolar macrophages. Am J Respir Cell Mol Biol 1993; 9:73-81
28. Hoffman OA, Standing JE, Limper AH. Pneumocystis carinii stimulates tumor necrosis factor α release from alveolar macrophages through a β-glucan-mediated mechanism. J Immunol 1993; 150:3932-3940
29. Neese LW, Standing JE, Olson EJ, et al. Vitronectin, fibronectin, and gp120 antibody enhance macrophage release of TNFα in response to Pneumocystis carinii. J Immunol 1994; 152:4549-4556
30. Little RC, Milliken GA, Stroup WW, et al. SAS system for mixed models, Cary, NC: SAS Institute, 1996
31. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999; 130:478-486
32. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial on etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-259
33. Yee A, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann Intern Med 2001; 135:27-31
34. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:70-74
35. Seitzer U, Swinder F, Stuber K, et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997; 9:787-790
36. Swinder C, Schnittger K, Bogunia-Kubik K, et al. TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. Eur Cytokine Netw 1999; 10:143-146
37. Seitzer U, Gerdes J, Muller-Quernheim J. Evidence for disease phenotype associated haplotypes (DR. TNF) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:279-283
38. Yamaguchi E, Itoh A, Hizawa N, et al. The gene polymorphism of tumor necrosis factor-α, is associated with the prognosis of sarcoidosis. Chest 2001; 119:753-761
39. Somoskovi AG, Zissel U, Seitzer J, et al. Polymorphisms at position -308 in the promoter region of the TNF-alpha and in the first intron of the TNF-beta genes and spontaneous and lipopolysaccharide-indoced TNF-alpha release in sarcoidosis. Cytokine 1999; 11:882-887
40. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345:1098-1105